tumor-associated antigen

Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.
Related to tumor-associated antigen: Cancer Antigens

tu·mor-·as·so·ci·at·ed an·ti·gen

antigens that are highly correlated with certain tumor cells. They are not usually found, or are found to a lesser extent, on normal cells.

tumor-associated antigen

Immunology, oncology A molecule–eg, CA 15.3, 19-9, CA-125, that may be associated with specific tumors–eg, lymphomas, carcinomas, sarcomas, melanomas; TAAs may elicit cellular and/or humoral immune responses against the tumor, but rarely defend the host against the tumor
Tumor-associated antigen types
Class 1 Highly specific for a particular tumor; they are present in one or only a few individuals and not found in normal cells, eg tumor-specific transplantation antigen
Class 2 Present in a number of related tumors from different Pts
Class 3 Present on normal and malignant cells, but are expressed in ↑ amounts in malignant cells  
Note: Class 2 antigens have the  greatest potential for clinically useful assays, as they are present in many tumors and are rarely observed in normal subjects
References in periodicals archive ?
Tumor-associated antigens and their correspondent autoantibodies are promising molecular markers for diagnostics and therapy of human malignancy.
In order to be successful, the vaccine had to overcome an important obstacle--the fact that the immune response can be so swift that the viral vector is neutralized before the immune system zeroes in on the real enemy: the tumor-associated antigens it carries.
For decades researchers have been looking at tumor-associated antigens as possible cancer markers and as signposts to better therapy, without the dramatic results reported this week However, even if the new antigen were to enter the commercial-production pipe-line soon, says Rauscher, it likely would be five to seven years before it would be widely available.
and the international Ludwig Institute for Cancer Research (LICR) have announced a multi-year clinical research collaboration focusing on a series of tumor-associated antigens (TAAs) for use in Celldex's Antigen Presenting Cell (APC) Targeting Technology.
In addition, the technology causes tumors to express their full complement of tumor-associated antigens, against which powerful anti-tumor (polyclonal, cytotoxic) immune responses are directed.
The company added ICT-107 is a patient-specific, dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells.
ImmunoCellular is conducting a Phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma.

Full browser ?